Volixibat potassium is under clinical development by Mirum Pharmaceuticals and currently in Phase II for Pruritus. According to GlobalData, Phase II drugs for Pruritus have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Volixibat potassium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Volixibat potassium overview
Volixibat potassium (SHP-626, LUM-002) is under development for primary sclerosing cholangitis and its associated pruritus and primary biliary cholangitis. It is administered through the oral route as a capsule. The drug candidate selectively targets apical sodium-dependent bile acid transporter (ASBT). The human apical sodium-dependent bile acid transporter (SLC10A2) belongs to the solute carrier family (SLC) of transporters and is an important carrier protein expressed in the small intestine.
It was also under development for the treatment of nonalcoholic steatohepatitis (NASH) by Shire, adult cholestasis (intrahepatic cholestasis of pregnancy), and Type 2 diabetes.
Mirum Pharmaceuticals overview
Mirum Pharmaceuticals is biopharmaceutical company that develops a pipeline of novel therapies for debilitating liver diseases. The company’s pipeline products include Maralixabat, minimally absorbed, orally administered investigational drug and Volixibat, a minimally absorbed agent designed to selectively inhibit ASBT. It develops products to treat rare cholestatic liver diseases that include progressive familial intrahepatic cholestasis (PFIC), alagille syndrome (ALGS), biliary atresia (BA), primary sclerosing cholangitis (PSC) and intrahepatic cholestasis of pregnancy (ICP). Mirum Pharmaceuticals is headquartered in Foster City, California, the US.
For a complete picture of Volixibat potassium’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Volixibat Potassium in Pruritus
Premium Insights
The gold standard of business intelligence.
